606 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Clear Creek Financial Management LLC

Key Points

• Clear Creek Financial Management LLC acquired a new position in Regeneron Pharmaceuticals, buying 606 shares valued at approximately $318,000 during the second quarter.
• Regeneron reported an EPS of $12.89 for the last quarter, exceeding analysts' estimates of $8.43, with a year-over-year revenue increase of 3.6%.
• The company declared a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%.

Clear Creek Financial Management LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 606 shares of the biopharmaceutical company's stock, valued at approximately $318,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Bar Harbor Wealth Management purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $4,712,000. Dohj LLC boosted its stake in Regeneron Pharmaceuticals by 105.1% in the second quarter. Dohj LLC now owns 1,208 shares of the biopharmaceutical company's stock worth $634,000 after buying an additional 619 shares in the last quarter. Traphagen Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 15.2% in the second quarter. Traphagen Investment Advisors LLC now owns 887 shares of the biopharmaceutical company's stock worth $466,000 after buying an additional 117 shares in the last quarter. Arcataur Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 3.7% in the second quarter. Arcataur Capital Management LLC now owns 1,038 shares of the biopharmaceutical company's stock worth $545,000 after buying an additional 37 shares in the last quarter. Finally, Bingham Private Wealth LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $224,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $564.63 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a market cap of $59.84 billion, a PE ratio of 14.23, a P/E/G ratio of 1.80 and a beta of 0.31. The business has a 50 day moving average of $573.95 and a 200 day moving average of $564.51. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.56 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analyst Ratings Changes

REGN has been the subject of a number of analyst reports. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Weiss Ratings reissued a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Finally, Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research note on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $817.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.